These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27607893)

  • 1. Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years.
    Matsushita T; Takehara K; Oishi K; Maeda S; Hamaguchi Y; Ishikawa S; Inokuchi M; Michiwa Y; Takehara K
    J Dermatol; 2017 Aug; 44(8):972-973. PubMed ID: 27607893
    [No Abstract]   [Full Text] [Related]  

  • 2. A patient with Parkinson's disease and dermatomyositis with serum anti-transcriptional intermediary factor 1-γ antibody.
    Murase C; Muro Y; Nakanishi H; Katsuno M; Akiyama M
    Eur J Dermatol; 2016 Dec; 26(6):617-618. PubMed ID: 27457413
    [No Abstract]   [Full Text] [Related]  

  • 3. Triple cancers concurrently detected in a case of antitranscriptional intermediary factor-1γ antibody-positive dermatomyositis.
    Kikuchi N; Ohashi T; Miura T; Nishibu A; Yamamoto T
    Int J Dermatol; 2017 Dec; 56(12):1516-1517. PubMed ID: 28884788
    [No Abstract]   [Full Text] [Related]  

  • 4. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
    Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
    Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
    Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically amyopathic dermatomyositis with anti-transcriptional intermediary factor 1-γ autoantibody positivity.
    Kanaoka M; Yamaguchi Y; Watanabe T; Akita A; Ototake Y; Ikeda N; Aihara M
    Rheumatology (Oxford); 2020 Oct; 59(10):e68-e69. PubMed ID: 32259242
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
    Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
    Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
    Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients.
    Gupta P; Suman S; Mishra M; Mishra S; Srivastava N; Kumar V; Singh PK; Shukla Y
    Proteomics Clin Appl; 2016 May; 10(5):564-73. PubMed ID: 27068564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
    Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
    Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
    Fujimoto M; Murakami A; Kurei S; Okiyama N; Kawakami A; Mishima M; Sato S; Seishima M; Suda T; Mimori T; Takehara K; Kuwana M
    J Dermatol Sci; 2016 Dec; 84(3):272-281. PubMed ID: 27693019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is proteomics starting to deliver on biomarkers discovery.
    Admon A
    Pigment Cell Melanoma Res; 2011 Dec; 24(6):1084-5. PubMed ID: 22216444
    [No Abstract]   [Full Text] [Related]  

  • 14. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
    Kubeček O; Soukup T; Paulík A; Kopecký J
    BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome.
    Palterer B; Vitiello G; Cammelli D
    Reumatismo; 2017 Aug; 69(2):75-77. PubMed ID: 28776361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1γ antibodies via line immunoassay versus immunoprecipitation.
    Westerdahl S; Hull CM; Clarke JT; Hansen CB; Rhoads JLW
    J Am Acad Dermatol; 2021 Feb; 84(2):559-561. PubMed ID: 32619611
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.
    Shah AA; Rosen A; Hummers LK; May BJ; Kaushiva A; Roden RBS; Armstrong DK; Wigley FM; Casciola-Rosen L; Visvanathan K
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):71-74. PubMed ID: 28628466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteome profiling for the identification of lung cancer signatures].
    Cho WC
    Zhongguo Fei Ai Za Zhi; 2012 Jul; 15(7):C4-7. PubMed ID: 23676999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-transcription intermediary factor 1-γ antibody-positive clinically amyopathic dermatomyositis complicated by interstitial lung disease and breast cancer.
    Ogawa M; Sugiura K; Yokota K; Muro Y; Akiyama M
    J Eur Acad Dermatol Venereol; 2016 Feb; 30(2):373-5. PubMed ID: 25346167
    [No Abstract]   [Full Text] [Related]  

  • 20. A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-γ.
    Meisterfeld S; Röber N; Conrad K; Beissert S; Aringer M; Günther C
    Br J Dermatol; 2017 Aug; 177(2):590-593. PubMed ID: 28314058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.